78 studies on GHRH analog class curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
This comprehensive review significantly expands our understanding of GHRH's multifaceted roles beyond its traditional endocrine function, particularly its involvement in cancer progression and lung inflammation. The c…
This research highlights a significant new therapeutic potential for GHRH antagonists, particularly MIA-602, in conditions involving blood-brain barrier dysfunction. Given their ability to protect brain microvascular …
These findings suggest GHRH agonists could be a novel and effective therapy for **heart failure with preserved ejection fraction (HFpEF)**, a condition with few treatment options. For clinicians and researchers, this …
This study proposes **sermorelin** as a potential new therapeutic avenue for recurrent glioma, one of the most difficult-to-treat cancers. For patients and clinicians dealing with aggressive, relapsed brain tumors—par…
This research provides crucial insights, suggesting that the anti-cancer effects of GHRH antagonists may be mediated, at least in part, through the induction of autophagy. Autophagy can lead to programmed cell death o…
This report highlights that the illicit drug market in Europe extends beyond commonly recognized categories like ED drugs. For users of peptides and other biopharmaceuticals, this is a stark reminder of the risks asso…
**Clinicians and peptide users combining GHS with GHRH analogs** (e.g., sermorelin or CJC-1295) should note the synergistic GH release depends entirely on hypothalamo-pituitary integrity — individuals with hypothalami…
**GH secretagogues represent a potentially superior alternative to exogenous GH** for older adults or clinicians pursuing somatotropic support, because they work through the body's own pulse-generation machinery rathe…
For clinicians and individuals managing hypogonadism, this review positions GHS like ipamorelin as a potential next-frontier adjunctive therapy to testosterone, specifically for targeting body composition issues like …
**CJC-1295's ability to bioconjugate to endogenous albumin in vivo after a single subcutaneous dose** fundamentally changes the pharmacokinetic calculus for GRF-based therapies — a single injection may sustain GH axis…
**Weekly or biweekly dosing** replacing daily GHRH injections is a substantial practical advance for any GH-optimization protocol. Clinicians and researchers investigating GH axis restoration — whether for **GH defici…
**Dosing frequency is the decisive variable** for CJC-1295 efficacy — every-24-hour administration is the threshold at which full growth rescue occurs in this model, while every-48-hour dosing yields only partial bene…
**Continuous GHRH stimulation does not blunt GH pulsatility** — a concern that had been a theoretical barrier to long-acting GHRH therapeutics. For clinicians and researchers, this validates the mechanistic rationale …
**Identifying reliable serum biomarkers of GH action is a critical unmet need** both for anti-doping enforcement and for titrating GH replacement therapy in clinical practice. The linear IGF-1 correlation with the imm…
The identification of CJC-1295 in an illicit preparation highlights the ongoing challenge of unregulated peptide drug availability and use, particularly within communities like bodybuilding. As a growth hormone-releas…
This new comprehensive testing protocol represents a significant upgrade for anti-doping agencies. By enabling the simultaneous screening of numerous peptides like CJC-1295, insulins, and growth factors in a single ru…
This research highlights a specific area of off-label, self-directed drug use that is largely unmonitored by healthcare professionals. For clinicians and public health officials, it underscores the need to be aware th…
This highly sensitive detection method provides sports anti-doping agencies with a powerful new tool for identifying the use of prohibited GHRHs like CJC-1295. For athletes and individuals using these peptides, this s…
This `I-PCR` assay represents a significant leap forward for anti-doping in equine sports and potentially beyond. Standard mass spectrometry methods are blind to CJC-1295 once it binds to plasma proteins, creating a m…
This groundbreaking method provides a definitive and highly sensitive tool for anti-doping agencies to confirm the illicit use of CJC-1295 in equestrian sports. The ability to detect conjugated CJC-1295, which has a p…
This research provides anti-doping laboratories with a validated, highly sensitive protocol for detecting **CJC-1295** and similar banned peptides. For athletes using these substances, this significantly increases the…
This study represents a significant advancement in the fight against doping in sports, specifically targeting growth hormone releasing hormone synthetic analogs. By identifying and characterizing previously unknown me…
For athletes and individuals using performance-enhancing peptides, this review underscores that sophisticated detection methods are already established for a wide array of compounds, including popular research peptide…
This hypothetical study highlights CJC-1295's potential as a long-acting growth hormone-releasing hormone (GHRH) analog, capable of providing sustained GH and IGF-1 elevation from a single dose. This sustained release…
This study is significant because it confirms the sustained efficacy and long-term safety of TH9507 (Tesamorelin) as a targeted treatment for HIV-associated lipodystrophy, a challenging side effect of ART. Reducing vi…
The premature termination of this Phase 2 study signifies that the potential of CJC 1295 as a viable treatment for HIV-associated visceral obesity remains entirely unconfirmed and unexplored through the completion of …